Evolution and Expansion of Therapies in the Global Cell and Gene Therapy Tools and Reagents Market 2020-2024 – PRNewswire

Posted on by

DUBLIN, Aug. 4, 2020 /PRNewswire/ -- The "Cell and Gene Therapy Tools, and Reagents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Gene and cell therapy are emerging as important tools to treat human health. Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers. The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene-based diseases. As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

The scope of this study encompasses an investigation of the market's cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. This research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. The report analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Region

Chapter 5 Market Breakdown by End User

Chapter 6 Government Regulations

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/p5fqx6

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the article here:

Evolution and Expansion of Therapies in the Global Cell and Gene Therapy Tools and Reagents Market 2020-2024 - PRNewswire

Preparing for an influx of cell and gene therapy approvals – – pharmaphorum

Posted on by

Cell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has ever seen. However, to fully realise the potential of these innovative therapies, integration across the supply chain is critical particularly with reimbursement and logistics.

As of the end of 2019, there were 17 cell and gene therapy products approved by the FDA. Now, there is more momentum than ever to bring these innovative medicines to market, and the FDA anticipates that it will approve 10 to 20 cell and gene therapy products a year within the next five years.

These therapies can offer new opportunities to patients with conditions where there are few treatment options and no cures. But the potential these products offer could remain largely unrealised if manufacturers and their partners are not prepared. Cell and gene therapy innovators and other stakeholders across the supply chain need to set themselves up for the greatest chance of success by addressing three key challenges: access barriers; logistics; and the need for stakeholder education.

Addressing access barriers through innovative payment models

While cell and gene therapies offer novel treatment to patients who have limited options, the cost associated with each product anywhere between $375,000 and $2 million can create significant access barriers. This challenge is compounded compared to traditional treatments that typically require multiple doses, as many cell and gene therapies are one-time treatments.

This situation increases the risk for payers covering the cell and gene therapy, given that the long-term magnitude and durability of the product is not known at the time of first regulatory approval and patients switch insurance carriers throughout their lifetimes.

Stakeholders across the industry have recognised the increasing need to consider alternatives to the standard payment system if cell and gene therapies are to become widely available

Stakeholders across the industry, such as manufacturers and payers, have recognised the increasing need to consider alternatives to the standard payment system if cell and gene therapies are to become widely available. As a result, a variety of payment models have been discussed:

We have already begun to see payers and manufacturers of cell and gene therapies attempt to adopt alternative payment models for their products, and more should continue to do so as additional therapies come through the approval pipeline. With a range of interdependencies that affect the success of cell and gene therapies, manufacturers need to develop their reimbursement strategy early in the commercialisation process. Its critical for manufacturers to consider various payment models for cell and gene therapies ahead of approvals so that they can maximise patient access for their products.

Ensuring therapies reach their patients

Manufacturers have noted that the delivery of critical shipments is one of the biggest challenges facing the advanced therapy industry, as if you cannot connect cell and gene therapies with patients their efficacy is irrelevant. The inclusion of patients into the cell and gene therapy supply chain, the potentially life-altering impact of the therapies and their high cost leaves no room for failure.

These therapies require timely delivery and maintaining precise temperature control is integral for the patient and the product. It calls for near-perfect execution ranging from mapping the best transportation route and planning for multiple contingencies (such as closed international borders), to how the packaging itself is evaluated, validated and used to maintain product integrity in all conditions.

Successful execution of these processes requires both manufacturers and other supply chain partners to maintain a robust logistics platform. Currently, many manufacturers are developing different logistics plans for each of the stages of a clinical trial, only to find out these processes dont scale when it is time to commercialise. Developing a plan early that can scale will position a product for success as more therapies are reviewed and approved. Manufacturers need to work with their 3PL and distribution partners to ensure control and oversight throughout the product journey to the patient failure to do so will put patient outcomes and commercial success at risk.

Promoting stakeholder education

Many stakeholders spanning payers, providers and patients do not understand the full clinical, logistical, operational, financial or reimbursement components associated with cell and gene therapies. Manufacturers can leverage the preliminary data theyve gathered throughout their initial commercialisation journey to support education and awareness efforts with these key stakeholders.

As payers conduct product reviews earlier and earlier in the development lifecycle, their demand for pre-approval information continues to grow. However, recent research shows that a gap still exists between the evidence sought by healthcare decision makers and what is being shared by manufacturers. COVID-19 has also caused delays in providing information in a timely and relevant manner, causing even more challenges for stakeholders.

The use of Pre-approval Information Exchange (PIE) is one way to combat these challenges. PIE allows manufacturers to communicate ahead of approval to partners with accurate, and unbiased information on products or indications, and share information early that may result in a place saved at the table for their product. This information equips stakeholders with the education needed to understand a products value story and positioning. Partners embedded in the industry particularly those with a patient-centric focus can also offer manufacturers the information they need to showcase the value of these products to patients.

The cell and gene therapy space is continuing to evolve. Through analysing payment models, working with partners to navigate logistical challenges and leveraging data, patients will have more opportunities than ever to access the next generation of medicines. Overall, the collaboration between stakeholders across the supply chain will facilitate a world in which we see 10 to 20 cell and gene therapies not only approved each year but out in the market directly impacting patients.

About the authors

Alex Guite is vice president services and alliances at World Courier. As strategy and services lead, Alex is responsible for developing and executing key strategic initiatives.Before joining World Courier in 2013 as head of pricing, Alex spent nearly 3 years with Oliver Wyman as a consultant in the Health and Life Sciences practice.

Ana Stojanovska is vice president, reimbursement & policy insights at Xcenda. She has extensive practical knowledge in working with key stakeholders to motivate local coverage of new products by both public and private payers and providing strategic compendia analyses and ongoing coding support. Prior to Xcenda, Ana worked for a bipartisan, non-profit health policy organization in Washington DC, where she helped lead research, health policy analysis, media outreach, and fundraising.

Link:

Preparing for an influx of cell and gene therapy approvals - - pharmaphorum

How Gene Therapy Helped Conner Run : Short Wave – NPR

Posted on by

Conner Curran, 9, (right) and his brother Will, 7, at their home in Ridgefield, Conn. The gene therapy treatment that stopped the muscle wasting of Conner's muscular dystrophy two years ago took more than 30 years of research to develop. Kholood Eid for NPR hide caption

Conner Curran, 9, (right) and his brother Will, 7, at their home in Ridgefield, Conn. The gene therapy treatment that stopped the muscle wasting of Conner's muscular dystrophy two years ago took more than 30 years of research to develop.

Gene therapy has helped a 9-year-old boy regain enough muscle strength to run. If successful in others, it could change the lives of thousands of children with Duchenne muscular dystrophy. NPR's Jon Hamilton tells us about Conner and his family...and one of the scientists who helped develop the treatment, a pioneer in the field of gene therapy.

This episode was produced by Abby Wendle, edited by Viet Le and fact-checked by Berly McCoy.

Read the rest here:

How Gene Therapy Helped Conner Run : Short Wave - NPR

Catalent’s Harmans Site Approved To Manufacture AveXis’ Gene Therapy – Contract Pharma

Posted on by

Catalent was approved by the U.S. FDA to produce commercial drug substance intermediate for AveXis spinal muscular atrophy (SMA) gene therapy at its manufacturing facility in Harmans, MD.

The approval follows an FDA inspection of the Harmans commercial-scale gene therapy manufacturing center in June. Under Catalents partnership with AveXis, a Novartis company, a dedicated suite space has been prepared at the Harmans facility for the commercial manufacture of this adeno-associated virus (AAV) gene therapy.

This is a significant milestone for Catalent and the gene therapy industry as a whole. Catalent is proud to be the first contract development and manufacturing organization to be approved for commercial gene therapy production, commented Manja Boerman, Ph.D., President of Catalent Cell & Gene Therapy. This approval allows us to leverage our now-licensed, state-of-the-art GMP commercial manufacturing facility, and our deep AAV expertise, to support AveXis as it delivers a life-changing treatment for patients.

Given the complexity and length of time required to make gene therapies, manufacturing is critically important, said Dannielle Appelhans, Chief Technical Officer for AveXis. This approval further complements our internal manufacturing capacity and, over time, will allow us to increase supply to meet growing patient needs.

Catalents Harmans commercial manufacturing facility, located near BWI airport, is equipped with single-use technology, and houses over 200,000 sq.-ft. of late-stage clinical and commercial-stage gene therapy production. The facility is one of Catalents five gene therapy facilities in Maryland providing clinical through commercial scale services, and houses multiple CGMP manufacturing suites, including fill/finish, central services and testing labs, warehousing, and supply chain capabilities.

Go here to read the rest:

Catalent's Harmans Site Approved To Manufacture AveXis' Gene Therapy - Contract Pharma

Sangamo and Novartis partner on gene therapies for autism – BioPharma-Reporter.com

Posted on by

The targets will be three undisclosed genes that are associated with certain neurodevelopmental disorders, such as autism spectrum disorder (ASD) and intellectual disability.

Sangamo Therapeutics will bring its genome regulation technology to upregulate the expression of key genes involved in neurodevelopmental disorders.

To gain access to this technology, Novartis will pay $75m (63m) upfront to Sangamo. Beyond this, Novartis could end up paying an additional $720m in developmental milestones.

According to Sangamo, the hope is that its zing-finger technology can active the expression of genes that are inadequately expressed in individuals with certain types of neurodevelopmental disorders.

Sangamos potentially therapy is currently delivered through adeno-associated viruses (AAVs) to the DNA level.

The terms of the agreement see the collaboration playing out over a three-year period, with Novartis holding the exclusive rights to zinc finger protein transcription factors (ZFP-TFs) targeting the three undisclosed genes at the center of the deal.

In addition, Novartis will have the option to license Sangamo proprietary AAVs delivery technology.

In terms of development, Sangamo will remain in the lead of research and associated manufacturing activities, though with funding from Novartis, and the latter company will perform supplementary research activities, before stepping in to take the lead in regulatory and commercial activities later in development.

Jay Bradner, president of the Novartis Institutes for BioMedical Research, said, The goal [of the partnership] is to create new gene regulation therapies that act at the genomic level, moving us beyond the symptom-focused treatments of today and toward therapies that can address some of the most challenging neurodevelopmental disorders.

Gene therapy has become a focus area for Novartis over the last few years, as the company invests into its cell and gene manufacturing capabilities and opens new treatment avenues for patients with genetic conditions.

Alongside these new developments, Novartis has also called for rethink of how healthcare is costed and what the value such treatments provide to society are, a debate that has come to the fore as the issue of the pricing of such therapies has arisen.

Continue reading here:

Sangamo and Novartis partner on gene therapies for autism - BioPharma-Reporter.com

Global Gene Therapy in Oncology Market 2020 Growth Statistics, New Opportunities, Competitive Outloo – PharmiWeb.com

Posted on by

Researchstore.bizhas published the latest research study onGlobal Gene Therapy in Oncology Market 2020 by Company, Type and Application, Forecast to 2025that presents a complete overview of the market with a detailed description of the global market. The report provides complete information about the advancing market trade and business data. The report highlights the dynamics of the market such as internal and external driving forces, restraining factors, risks, challenges, threats, and opportunities. The complete view linked with the progress of this globalGene Therapy in Oncologymarket by the significant players involved in this business. Analysts of this research report predict the financial attributes such as investment, pricing structures along with the profit margin.

NOTE:This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-depth analysis ofGene Therapy in Oncologymarket.

DOWNLOAD FREE SAMPLE REPORT:https://www.researchstore.biz/sample-request/50214

The report delivers brief information on the competitors and the specific growth opportunities with key market drivers. Complete market analysis is given by segmenting the report by companies, region, type, and applications in the report. Top players also analyzed by splitting the globalGene Therapy in Oncologymarket by product type and applications/end industries. The overall report encompasses many aspects of the industry like market size, market status, market trends, and forecast. Additionally, development trends, competitive landscape analysis, and key regions development status has been demonstrated. It also focuses on a product analysis, application analysis, competitive strategies, and strategies impacting the industry. An expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, and forecasting for 2020 to 2025 time-period has been given.

The report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution. With mergers and acquisitions and fast building of product portfolio, key players in the globalGene Therapy in Oncologymarket are analyzed to take charge of a leading share. Some of the tough competitors in the global market areBristol-Myers Squibb, Editas Medicine, Amgen, Cold Genesys, CRISPR Therapeutics, Advantagene, Idera Pharmaceuticals, Bio-Path Holdings, AstraZeneca, Geron Corp, Mologen AG, Oncotelic, Intellia Therapeutics, Sillajen Biotherapeutics, Oncolytics Biotech, Merck, Johnson & Johnson, Shenzhen SiBiono GeneTech, Oncosec, Marsala Biotech, Tocagen, UniQure, Ziopharm Oncology.

Geographically, this market report studies the following key geographical regions:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Moreover, the report explains the summary of all products and major changes occurring currently in the globalGene Therapy in Oncologyindustry. Later, production and production value estimates by type, estimates of key producers, and production and production volume estimates by region added in the research report. The noticeable feature of this market covered here includes numerous dynamic and static aspects of the businesses. The report comprises of the regional development status of the regions. This report assesses data type concerning various regions includes capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export, etc.

ACCESS FULL REPORT:https://www.researchstore.biz/report/global-gene-therapy-in-oncology-market-2020-50214

Table of Contents:1 Market Overview2 Company Profiles3 Market Competition, by Players4 North America Market Size and Forecast by Countries5 Europe Market Size and Forecast by Countries6 Asia-Pacific Market Size and Forecast by Countries7 South America Market Size and Forecast by Countries8 Middle East & Africa Market Size and Forecast by Countries9 Market Size Segment by Type10 Market Size Segment by Application11 Research Findings and Conclusion12 Appendix

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@researchstore.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About UsResearchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@researchstore.bizWeb:www.researchstore.biz

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Original post:

Global Gene Therapy in Oncology Market 2020 Growth Statistics, New Opportunities, Competitive Outloo - PharmiWeb.com

Research shows promising results for LHON gene therapy – Ophthalmology Times

Posted on by

This article was reviewed by Alvin Luk, PhD, MBA, CCRA

Results from two investigator-initiated studies demonstrate that a single intravitreal injection of rAAV2-ND4 (Neurophth Therapeutics Inc.) is associated with long-term safety and durable efficacy for improving vision in patients with Leber hereditary optic neuropathy (LHON), according to Alvin Luk, PhD, MBA, CCRA.

The research is comprised of a single center study including 9 patients followed for 75 to 90 months and a multicenter, international trial including 159 patients followed for up to 12 months, with observation ongoing.

Related: TANGO: Helping target genes produce more protein

Across the entire cohort, there were no serious or severe adverse events, and efficacy data showed that a majority of patients benefited with significant and sustained improvement in BCVA.

LHON is a rare inherited visual disorder that leads to bilateral vision loss and for which there is currently no effective treatment, said Luk. These 2 studies contain the largest and longest follow-up of patients treated withthis gene therapy. Based on the results, we are very excited about its potential impact for restoring vision and greater independence for patients with LHON.

Luk, the CEO at Neurophth Therapeutics Inc., noted gene therapy also is offering a positive impact on treatment.

The gene therapy restores function of the mitochondrial respiratory chain in retinal ganglion cells by delivering the NADH ubiquinone oxidoreductase subunit 4 (ND4) gene.

A series of preclinical studies confirmed that the intravitreal treatment resulted in targeted gene delivery and provided evidence of its safety.

Related: Gene therapy zeroes in as LHON treatment

Importantly, the confocal microscopy analysis confirms that rAAV2-ND4 reaches the targeted areas in the eyes where the pathological changes of LHON occur, Luk said. Therefore, providing support to the hypothesis that treatment with rAAV2-ND4 may alleviate the underlying cause of the vision loss in patients with LHON.

The clinical studies of rAAV2-ND4 gene therapy reported by Luk have been led by Bin Li, MD, PhD, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.

The first study was initiated in 2011. Known as SEE4 LHON (NCT01267422), it included 3 patients aged younger than 12 years who received 0.5 x 1010 vector genome (vg)/eye and six patients aged older than 12 years who were treated with a dose of 1.0 x 1010vg/eye.

According to investigators, the injections were given into 1 eye in an outpatient procedure and had a volume of 0.05 mL.

Although planned follow-up was initially for 12 months, 8 of the 9 patients have continued follow-up until today, Luk said.

Related: Study targets ocular damage from chronic intravitreal injections

According to Luk, there have been no late toxicities noted nor any abnormalities in intraocular pressure (IOP) in extensive laboratory testing, which includes assessments of hepatic, renal, and immune function.

Efficacy is being evaluated with measurement of the logarithm of the minimum angle of resolution (logMAR) in best-corrected visual acuity (BCVA).

Luk pointed out that at 3 months post-injection, 8 patients (89%) demonstrated improvement from baseline, and 6 of 9 patients (67%) maintained improvement at 3 years.

They also noted that the BCVA response was maintained at month 70 by 5 of the 6 responders who achieved a mean BCVA gain of 0.68 logMAR.

Patients in this study also benefited with some improvement in the untreated eye, Luk said. This kind of bilateral response was also seen in the second larger trial of this therapy and is consistent with observations by other groups working on gene therapy for this inherited eye disease.

Based on the encouraging results of SEE4LHON, a larger scale study named 4-HOPE was launched in 2017.

Related: Research targets precision dosing for gene, cell therapy

All patients were treated at three investigational sites in China and 10 patients are continuing follow-up at their local centers in Argentina.

Luk pointed out that the study enrolled 159 patients aged 6 years or older who received a unilateral injection with 1.0 x 1010 vg/eye.

The safety review showed there were no drug-related adverse events. Ocular hypertension was the most common adverse event that patients experienced, but it is related to the course of oral steroid treatment that is given in conjunction with the injection, Luk explained.

The IOP elevations are generally mild and resolve spontaneously once the steroid treatment is ended, he said.

Of the 159 enrolled patients, 106 had data available from a 12-month follow-up visit. Of the 106 patients, Luk noted that 63% showed an improvement from baseline BCVA with an average gain of 0.3 logMAR.

Related: Greater IOP-lowering with iStent inject

It is important to point out that the patients enrolled in this study represent a heterogenous group with a wide range of ages, time since diagnosis, and baseline BCVA values, Luk concluded. We would not be surprised to see even better efficacy results in a cohort enrolled using narrower inclusion criteria.

Luk noted some of the patients in the study also benefited with bilateral BCVA improvement.

Taking improvements ofinjected and noninjected eyes into consideration from baseline to 12 months post treatment, 43.7% patients who classified as legally blind by World Health Organizationcriteria ( > 1.3 logMAR) were recovered to low (> 0.5 to 1.3 logMAR) or normal ( 0.5 logMAR) vision.Read more by Lynda Charters

--

Alvin Luk, PhD, MBA, CCRAe:alvin.luk@neuropth.comLuk is an employee of Neurophth Therapeutics Inc, but has no other relevant financial interests to disclose.

Link:

Research shows promising results for LHON gene therapy - Ophthalmology Times

The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 – Yahoo Finance

Posted on by

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report. The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.

New York, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025" - https://www.reportlinker.com/p05827567/?utm_source=GNW 90% during the period 20192025.

The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic disorders, and other rare diseases across the globe. The prevalence of cancer and diabetes is increasing in the global population, which is influencing the growth of the market. There is a large unmet need in the treatment available, which is filled by cell and gene therapies. The market is growing due to the increased availability of funding from various public and private institutions. Besides, there is increased support from regulatory bodies for product approval. Several governments are creating awareness of cell and gene therapies in the population.

The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period: Increase in Strategic Acquisition Activities Increased Funding for Cell & Gene Therapy Products Expanding Applications of Cell and Gene Therapies Increased in the Patient Pool

The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2019?2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market. Cell And Gene Therapy Market Segmentation The global cell and gene therapy market research report includes a detailed segmentation by product, disease, end-user, and geography. In 2019, the cell therapy segment accounted for a market share of over 53% in the global cell and gene therapy market. The segment is expected to grow at a steady rate during the forecast period due to the increase in the target population and the rise in the number of countries preferring cell therapies in their patients. Increased therapeutic benefits are attracting several countries to invest in this technology and conduct a high number of clinical trials. However, the lack of advanced infrastructure in developing countries is hindering the growth of the segment.

In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

Segmentation by Product Cell Therapy Gene Therapy Segmentation by Disease Dermatology Musculoskeletal Oncology Genetic Disorders Others Segmentation by End-user Hospitality Cancer Care Centers Wound Care Centers Ambulatory Surgical Centers Others

INSIGHTS BY GEOGRAPHY In 2019, North America accounted for a share of over 60% of the global cell and gene therapy market. There are more than 530 regenerative medicine companies, including cell and gene therapy manufacturing developers. The number of products approved in North America grew significantly in 2019, with developers filed for marketing authorization for 10+ regenerative medicines, many of which we expect to be approved in 2020. Within the next 12 years, the number of approved gene therapies is expected to double. The US and Canada are the major contributors to the cell and gene therapy market in North America. Regulatory bodies are supporting several investigational products, fast track approvals, RMAT designation for the faster approval of the product into the market. The alliance for regenerative medicine and Medicare and Medicaid is working together to bring the structured reimbursement channels for cell and gene therapies.

Segmentation by Geography North America o US o Canada Europe o UK o Germany o France o Spain o Italy APAC o China o Japan o South Korea o Australia o India Latin America o Brazil o Mexico Middle East & Africa o Saudi Arabia o Turkey o South Africa o UAE

INSIGHTS BY VENDORS The global cell and gene therapy market is highly dynamic and characterized by the presence of several global, regional, and local vendors offering a wide range of therapies. Dendreon, Gilead Sciences, Novartis, Organogenesis, Osiris Therapeutics, Vericel, Amgen, and Spark Therapeutics are the leading players in the market with significant shares. Vendors such as NuVasive, APAC Biotech, Nipro, Orthocell, bluebird bio, J-TEC, and Terumo are the other prominent players in the market with a presence, especially in the cell therapy market. Most leading players are focusing on implementing strategies such as product launches and approvals, marketing and promotional activities, acquisitions, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market.

Prominent Vendors Gilead Sciences Spark Therapeutics Novartis Organogenesis Amgen Osiris Therapeutics Dendreon Vericel

Other Prominent Vendors Anterogen Tego Sciences Japan Tissue Engineering JCR Pharmaceuticals Medipost MolMed AVITA Medical CollPlant Biosolution Stempeutics Research Kolon Tissue Gene Orchard Therapeutics Sibiono GeneTech NuVasive Corestem Pharmicell Shanghai Sunway Biotech RMS Regenerative Medical System Takeda Pharmaceutical Company CHIESI Farmaceutici CO.DON AnGes GC Pharma Human Stem Cells Institute JW CreaGene APAC Biotech Nipro Terumo Orthocell bluebird bio

Key Questions Answered 1. What is the cell and gene therapy market size and growth rate during the forecast period? 2. What are the factors impacting the growth of the cell and gene therapy market share? 3. How is the growth of the healthcare segment affecting the growth of the cell and gene therapy market? 4. Who are the leading vendors in the cell and gene therapy market, and what are their market shares? 5. Which product type/ end-user type/region is generating the largest revenue in the Asia Pacific region?Read the full report: https://www.reportlinker.com/p05827567/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More:

The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 - Yahoo Finance

Detailed Information on Gene Therapy Market 2020 | Covid-19 Impact Analysis | Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio,…

Posted on by

Global Gene Therapy Market report forecast to 2026 investigate the Impact of COVID-19 on Industry further market size, manufactures, types, applications and key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gene Therapy in these regions. This report also studies the global Gene Therapy market share, competition landscape, status share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample copy along with Few Details- https://www.worldwidemarketreports.com/sample/364919

Leading Players from the market are covered in this report- Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon

Impact of Covid-19 on Gene Therapy Industry 2020

Gene Therapy Market report analyses the impact of Coronavirus (COVID-19) on the Gene Therapy industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Gene Therapy market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

Download Sample TOC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies-https://www.worldwidemarketreports.com/sample/364919

Market Segments:

Based on Types, the Gene Therapy Market is Classsified as Ex vivo, In vivo

Based on Application, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others

Gene Therapy Market Report Provides Comprehensive Analysis as Following:

Study on Table of Contents:

During thePandemic, get Discount upto 50% https://www.worldwidemarketreports.com/discount/364919

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Read the rest here:

Detailed Information on Gene Therapy Market 2020 | Covid-19 Impact Analysis | Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio,...

‘He was defending himself and his family’: Homeowner shoots, kills suspected invader – WTSP.com

Posted on by

LAND O' LAKES, Fla. A man believed to have been upset at a family supporting his estranged wife broke into their home Saturday afternoon and was shot to death by its homeowner, the sheriff said.

Deputies responded around 12:30 p.m. to the home in the Sunset Lakes subdivision, where 55-year-old Ronald Fleet was pronounced dead.

Fleet kicked in the door of the family's home and was met by the homeowner armed with a gun, Pasco County Sheriff Chris Nocco said. Fleet also was armed and was fired upon but returned a round of gunfire before exiting.

Fleet then "charges" into the house, Nocco said, forcing the homeowner to shoot and kill him.

"He was defending himself and his family," Nocco said. "Any loss of life is tragic, but the victim was utilizing his Second Amendment rights to protect himself and his family from the fear of Ronald who was carrying a gun, kicking in a door, trying to harm them.

"I can't imagine the fear that they were going through, but I'm very happy the fact that he was able to defend himself and his actions."

Nocco said the family was helping to protect the woman during divorce proceedings get out of a "horrific marriage." Records show Fleet had prior arrests for domestic battery and driving under the influence.

No one else was hurt in the shooting.

What other people are reading right now:

Read more:

'He was defending himself and his family': Homeowner shoots, kills suspected invader - WTSP.com

What to Know in Washington: Stimulus Talks Near Edge of Collapse – Bloomberg Government

Posted on by

Negotiations on a new coronavirus relief bill edged toward the brink of collapse after a meeting yesterday between White House officials and top congressional Democrats ended with each side accusing the other of being unwilling to compromise and the biggest issues far from resolved.

The four negotiators, Speaker Nancy Pelosi (D-Calif.), Senate Minority Leader Chuck Schumer (D-N.Y.), White House Chief of Staff Mark Meadows and Treasury Secretary Steven Mnuchin, emerged from a more than three-hour meeting with little to show and with no guarantee they would resume talks today.

Mnuchin and Meadows said that while talks made progress on a few areas of possible compromise, there still are disagreements on the topline numbers for a stimulus bill and on the biggest individual provisions, including aid to state and local governments that Democrats want.

The differences are still significant, Meadows said.

Pelosi said Republicans are not facing up to the gravity of the economic calamity facing the U.S. Schumer said the meeting was disappointing because the White House wasnt willing to meet them in the middle.

We are very far apart, Pelosi said. Its most unfortunate.

The talks began under the pressure of expectations from financial markets and the threat from President Donald Trump that hell act unilaterally to restore some of the stimulus measures that ran out during a stalemate in Congress.

Meadows and Mnuchin said they will consult with Trump and call Pelosi and Schumer today to determine if it makes sense to meet. Schumer made clear Democrats are willing to keep talking.

Todays release of the Labor Departments July jobs report may influence whether talks resume. While high-frequency data have indicated a slowdown in economic activity in recent weeks, the report is forecast to show another positive, though modest, gain in jobs. Still, the unemployment rate is expected to remain higher than it was at the peak of the deep recession that followed the financial crisis in 2008.

If the jobs report comes in better than expected, it could stiffen the resistance of the White House to spending anywhere close to $3.5 trillion Democrats have been demanding in the talks. A worse than expected report could hasten them to a conclusion. Read more from Erik Wasson, Steven T. Dennis and Laura Litvan.

Signs Are Pointing to a Far Less Rosy Jobs Report: After a surge in coronavirus cases across the U.S., all signs point to a slowdown in job gains last month or worse. The report is forecast to show a 1.48 million increase in nonfarm payrolls in July, the median estimate in projections ranging from a 600,000 decline to a gain of 3.2 million. Thats following a combined rise of 7.5 million in May and June, which just started to make up the 22 million drop over the first two months of the pandemic, Reade Pickert and Maeve Sheehey report.

The House meets at 10 a.m. for a pro forma session.

The Senate will reconvene Monday at 3 p.m., with no votes currently planned.

No hearings are scheduled in the House or Senate as of this morning.

Hawaii State Democratic Sen. Kahele Favored to Succeed Gabbard: A Democratic House primary tomorrow in Hawaii is more of a coronation than a competition. State Sen. Kai Kahele is an overwhelming favorite to win a four-candidate election in the 2nd District, which includes most of Hawaii outside Honolulu. Rep. Tulsi Gabbard (D) is retiring.

None of Kaheles competitors in the primary reported raising $5,000, according to Federal Election Commission data as of July 19.

Kahele got a big head start when he announced in January 2019 he would run against Gabbard, who had just announced her candidacy for the 2020 Democratic presidential nomination. Gabbard, whose White House bid faltered, announced in October 2019 she wouldnt seek re-election to the House. Read more from Greg Giroux.

Judge Denies GOP Bid to Stop House Proxy Voting: A federal judge rejected a bid by House Republicans to block proxy-voting procedures Democrats created for members who are quarantined or otherwise house-bound during the Covid-19 pandemic. U.S. District Judge Rudolph Contreras said that House lawmakers may continue to vote by proxy because the U.S. Constitution protects members of Congress from civil suits contesting legislative acts. David Yaffe-Bellany has more.

Pipeline Bill Passed: The Senate last night by unanimous consent passed legislation (S. 2299), with a substitute amendment by Sen. Roger Wicker (R-Miss.), that would authorize appropriations through fiscal 2023 for some pipeline safety programs, among other provisions. The bill now moves to the House. The chamber also passed S. 4075, legislation to amend the Public Works and Economic Development Act of 1965, introduced by Shelley Moore Capito (R-W.Va.), chairwoman of the Senate Environment and Public Works Transportation and Infrastructure Subcommittee.

Oil Profit by U.K. Firm Stirs Scrutiny: A Senate Democrat is calling on federal regulators to conduct a deep analysis of whether oil markets are susceptible to manipulation following a Bloomberg News report that documented how a small London firm made as much as $500 million when the price of oil went negative in April. Senate Banking Committee ranking member Sherrod Brown (D-Ohio) said Vega Capital Londons trading profits show additional regulatory safeguards are necessary. Ben Bain, Liam Vaughan, and Kit Chellel have more.

Rubio Wants More Time to Count Votes: Sen. Marco Rubio (R-Fla.), acting chairman of the Senate Intelligence Committee, is warning of potential chaos in the election because of the pandemic and wants to give states nearly two months to count ballots. Under Rubios measure, states would have until Jan. 1 to certify electors to the Electoral College rather than Dec. 8. Read more from Ryan Teague Beckwith.

Senate Confirms SEC Nominees Peirce, Crenshaw: Hester Peirce and Caroline Crenshaw will serve as SEC commissioners until at least 2024 after receiving the Senates endorsement. The Senate confirmed Peirce and Crenshaw for terms on the Securities and Exchange Commission by voice vote. Trump nominated them in June. Read more from Andrew Ramonas.

Peters Solicits Americans Postal Delay Complaints: Americans who have had critical mail such as election ballots or medicine delayed or go missing should report it to Sen. Gary Peters (D-Mich.), the top Senate Democrat on the Homeland Security and Governmental Affairs Committee. Peters is investigating the reported service delays following recent changes, Shaun Courtney reports. Ive heard firsthand from constituents, postal workers and local officials in Michigan who have encountered problems with the timely and dependable service they count on to conduct business, get prescription medications and critical supplies, and even exercise their right to vote, Peters said in a press release.

Hagerty Wins Tennessee GOP Primary for Alexanders Seat: Bill Hagerty won the Tennessee Republican primary for the seat held by retiring Sen. Lamar Alexander (R-Tenn.), AP reports. Trump endorsed Hagerty, his former ambassador to Japan, in a 15-way Republican race. Hagerty, a former private equity executive who was Tennessees economic and community development commissioner, faced competition from Manny Sethi, an orthopedic trauma surgeon and son of Indian immigrants.

Commission Turns Down Request for Fourth Debate: The Commission on Presidential Debates yesterday rejected the Trump campaigns request for an additional debate against Democrat Joe Biden in early September as well as its push to pick moderators for the three scheduled debates. Read more from Jennifer Epstein.

Trump Campaign Sees Jump After Virus Briefings: Trumps new campaign manager credited the revival of the presidents daily briefings with narrowing the gap between him and Biden, saying that when the president speaks its a needle mover. Bill Stepien took over as the presidents campaign manager in July. Since Stepien stepped in, Trump has changed his public approach to the pandemic. Mario Parker has more.

Trump Says Biden Is Against God: Trump said Biden was opposed to God and religion, turning to cultural issues during a speech on the economy. Hes going to do things that nobody ever would ever think would be possible because hes following the radical left agenda, Trump said during an Ohio event. Take away your guns, destroy your Second Amendment, no religion, no anything. Hurt the Bible, hurt God. Hes against God, hes against guns.

Biden slammed Trumps comments, calling the president an insecure bully. For President Trump to attack my faith is shameful. Its beneath the office he holds and its beneath the dignity the American people so rightly expect and deserve from their leaders, Biden said in a statement. Ryan Teague Beckwith has more.

Biden Apologizes For Comments on Racial Diversity: Biden apologized late yesterday for comments he made earlier in the day that suggested that the African-American community was not diverse. In no way did I mean to suggest the African-American community is a monolith not by identity, not on issues, not at all, Biden said in an series of tweets. In an interview with Black and Latino journalists published early yesterday, Biden said that unlike the African-American community, with notable exceptions, the Latino community is an incredibly diverse community with incredibly diverse attitudes about different things. Read more from Jennifer Epstein.

Kanye West Plays Spoiler: Rapper Kanye West all but confirmed he is running a spoiler campaign for the presidency to draw votes from Biden, amid reports that GOP operatives are helping him get on the ballot. Im not going to argue with you. Jesus is King, West told a Forbes reporter after the reporter pointed out the artist cannot win since he wont be on enough ballots to garner the necessary 270 electoral votes. Read more from Ryan Teague Beckwith.

Virginia Drops Absentee Ballot Witness Requirement: Virginia has agreed to extend its suspension of its witness requirement for absentee ballots for the November general election due to the continued presence of Covid-19 in the state, according to a recent filing in federal court. Election officials and the League of Women Voters of Virginia agree that enforcing the requirement during the coronavirus pandemic would impose a serious burden on the right to vote, the parties told the U.S. District Court for the Western District of Virginia Wednesday. Read more from Porter Wells.

Trump Widens China Tech Attack: Trump signed a pair of executive orders yesterday prohibiting U.S. residents from doing business with the Chinese-owned TikTok and WeChat apps beginning in 45 days, citing the national security risk of leaving Americans personal data exposed. The bans mark a significant escalation by Trump in his confrontation with Beijing as the U.S. seeks to curb Chinas power in global technology.

The move coincides with Trumps push for the sale of TikTok, the popular video app owned by ByteDance, to an American company. It threatens penalties on any U.S. resident or company that conducts transactions with TikTok, WeChat or their owners after the orders take effect. To protect our Nation, I took action to address the threat posed by one mobile application, TikTok. Further action is needed to address a similar threat posed by another mobile application, WeChat, Trump said in the order against WeChat, released minutes after the TikTok measure. Read more from Saleha Mohsin, Shelly Banjo, Nick Wadhams and Justin Sink.

U.S. Seeks Tighter Disclosures for China Listings: A high-powered U.S. panel recommended tightening the disclosure requirements for Chinese companies listed on American exchanges, following mounting concerns about the possible exposure of investors to fraud. The Working Group on Financial Markets said it will recommend the Securities and Exchange Commission bolster requirements governing the submission of audit papers from Chinese listingsboth new and existingto the main American accounting-standards agency. Read more from Saleha Mohsin and Jenny Leonard.

Trump to Reimpose Some Tariffs on Canada: The Trump administration will reimpose tariffs on some Canadian aluminum imports, striking a crucial trade partner only weeks after the presidents landmark North American trade deal went into effect. Trump announced that he was removing Canadas exemption from 10% tariffs, effective Aug. 16. Read more from Joe Deaux, Josh Wingrove, Jenny Leonard, and Jennifer Jacobs.

U.S., India Plan Meetings: The U.S. and India will hold ministerial meetings and discussions later this year, according to a State Department read out issued after Secretary of State Michael Pompeos phone call with Indian foreign minister Subrahmanyam Jaishankar, Archana Chaudhary reports.

Roberts Court Draws Partisan Fire: Pretty much no one is happy with U.S. Chief Justice John Roberts. And that may suit him just fine. Vice President Mike Pence joined a chorus of right-wing criticisms of the Supreme Courts leader, telling CBN News on Wednesday that the Republican-appointed Roberts has been a disappointment to conservatives. Those attacks come even as liberals say the real problem is Robertss larger body of work and steady effort to bolster conservative legal causes.

Together, the dueling critiques are bolstering an image Roberts has long sought to foster that of a court that decides cases independently, not based on ideological leanings or party preference. Read more from Greg Stohr.

Main Street Program Attracts Handful of Borrowers: The Federal Reserves Main Street Lending Program had attracted just eight borrowers as of July 27, according to a report released yesterday by the central bank. Borrowers took out $10 million through the New Loan Facility and $70.9 million through the Priority Loan Facility, which provides potentially larger amounts to more leveraged companies. Read more from Catarina Saraiva.

DeWine Says Positive Test for Covid-19 Was False: Gov. Mike DeWine, a Republican who has aggressively pushed public-health measures for Ohio, said last night that an initial positive test for Covid-19 was apparently a false result. DeWine took an antigen test early in the day. But then the governor said later that a second test using the PCR or nucleic acid method came back negative, as did tests for his wife and staff members. Stephen Merelman has more.

Safety Agency Moves Ahead with Quorum of One: The new chairwoman of a federal agency that investigates major industrial accidents has an unusual problem: shes the only person on its five-member board, and Trump wants it shut down. Katherine Lemos said she plans to continue the U.S. Chemical Safety Boards work after securing a legal opinion that she can operate as a quorum of one. In her first interview since taking office, Lemos vowed to get the roughly 35-person agency with a checkered-past off the problem child list, while promising to be tough on chemical and petroleum industries it oversees. Read more from Ari Natter and Alan Levin.

EPA Finalizing Second Term Trump Agenda Plans: The EPA is wrapping up its agenda for a second Trump administration term, as it gears up to release key air and water regulations including the rewrite of methane standards and revisions to the lead rule, Administrator Andrew Wheeler said yesterday. We are, at this point, putting our final touches on our agenda for the second term, he said. Amena H. Saiyid has more.

CandyPAC Lead Onboarded from Lodging Association: The National Confectioners Association has hired Alyssa Clevenger away from the American Hotel & Lodging Association to oversee the groups political action committee, the CandyPAC. The CandyPAC has donated about $420,000 to political committees since January 2019, Megan R. Wilson reports.

Trump Fails to Stall Rape Accusers Lawsuit: Trump cant stall a defamation lawsuit filed by a New York advice columnist who claims he raped her two decades ago, a judge ruled, allowing the two sides to start digging for evidence. E. Jean Carroll, who went public with her claims last year and sued Trump after he called her a liar, will now seek to depose the president as well as get a DNA test from him to compare with a sample on a dress the author said she wore at the time of the alleged attack. Read more from Erik Larson.

With assistance from Emily Wilkins, Megan R. Wilson, and Shaun Courtney

To contact the reporters on this story: Zachary Sherwood in Washington at zsherwood@bgov.com; Brandon Lee in Washington at blee@bgov.com

To contact the editors responsible for this story: Giuseppe Macri at gmacri@bgov.com; Loren Duggan at lduggan@bgov.com; Michaela Ross at mross@bgov.com

Continued here:

What to Know in Washington: Stimulus Talks Near Edge of Collapse - Bloomberg Government

Trump calls Biden Sleepy but cant say Yosemite, Thailand: Darcy cartoon – cleveland.com

Posted on by

CLEVELAND, Ohio -- President Trump has nicknamed Joe Biden Sleepy Joe, portrayed him as feeble, challenged him to a cognitive test, said hes anti-God, but mispronounced Thailand after also mispronouncing Yosemite, all while Biden was seen vigorously riding a mountain bike.

At a campaign stop at the Whirlpool factory in Clyde, Ohio Thursday, Trump mispronounced Thailand, saying THIGH-land. Tuesday at a bill signing event, Trump had also mispronounced Yosemite twice. Trump pronounced it Yo-SEMIGHTS then Yo-se-min-NIGHT before giving up on pronouncing it Yo-sem-i-tee. You would have thought the President of the United States would have heard Thailand and Yosemite National Park before, or at least Yosemite Sam, the cartoon character.

Trump having THIGH-land on his mind is really not a surprise given his infidelities, comments about women physically or if youve seen the size of his thighs in golf attire.

During his Whirlpool speech, Trump also said the devout Catholic Biden was against God.

Take away your guns,destroy your Second Amendment. No religion, no anything. Hurt the Bible, hurt God. Hes against God, hes against guns, hes against energy, our kind of energy.

The last time Trump was seen at a church was when he had protesters cleared from Lafayette Square next to The White House so he could have a brief photo-op in front of St. Peters church holding a Bible upside down.

In between mispronouncing Yosemite and Thailand, Trump tweeted a challenge for Biden to take the simple cognitive test he bragged about acing.

He cannot pass the test I ACED. He should give it a try.

All the time this was going on, footage was released of Biden driving his 1967 Corvette Stingray and vigorously riding a mountain bike while wearing a mask and cracking a joke.

Biden was driving his vintage vette for an ad. He had previously been seen driving it on a segment of Jay Lenos Garage in 2016. The classic car was a wedding gift to Biden from his father, who worked at a Chevy dealership.

When have you ever seen Trump driving anything besides a golf cart, let alone riding a bike?

At 77, Bidens not Sleepy Joe hes Spry Joe.

Read more here:

Trump calls Biden Sleepy but cant say Yosemite, Thailand: Darcy cartoon - cleveland.com

GCI Liberty, Inc. (GLIBA) Gains 40.35% in one Year: Whats Next? – The News Heater

Posted on by

GCI Liberty, Inc. (NASDAQ:GLIBA) went up by 1.85% from its latest closing price when compared to the 1-year high value of $82.20 and move up 1.7%, while GLIBA stocks collected 6.67% of gains with the last five trading sessions. Barron's reported on 08/07/20 that How to Invest in Lennar and Other Dual-Share Companies at a Discount

GLIBA stocks went up by 6.67% for the week, with the monthly jump of 15.15% and a quarterly performance of 30.96%, while its annual performance rate touched 40.35%. The simple moving average for the period of the last 20 days is 9.18% for GLIBA stocks with the simple moving average of 22.55% for the last 200 days.

Many brokerage firms have already submitted their reports for GLIBA stocks, with The Benchmark Company repeating the rating for GLIBA shares by setting it to Buy. The predicted price for GLIBA socks in the upcoming period according to The Benchmark Company is $82 based on the research report published on February 26, 2020.

B. Riley FBR, on the other hand, stated in their research note that they expect to see GLIBA stock at the price of $92, previously predicting the value of $89. The rating they have provided for GLIBA stocks is Buy according to the report published on January 16, 2020.

Citigroup gave Buy rating to GLIBA stocks, setting the target price at $80 in the report published on November 12, 2019.

After a stumble in the market that brought GLIBA to its low price for the period of the last 52 weeks, GCI Liberty, Inc. was able to take a rebound, for now settling with 1.73% of profit for the given period.

The stock volatility was left at 1.97%, however, within the period of a single month, the volatility rate increased by 2.17%, while the shares surge at the distance of +14.03% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +20.49% upper at the present time.

In the course of the last 5 trading sessions, GLIBA went up by +6.67%, which changed the moving average for the period of 200 days to the total of +27.06% of gains for the stock in comparison to the 20-day moving average settled at $77.10. In addition, GCI Liberty, Inc. saw 18.02% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at GCI Liberty, Inc. (GLIBA), starting from DUNCAN RONALD A, who sold 5,171 shares at the price of $60.66 back on May 15. After this action, Rushing now owns 156,517 shares of GCI Liberty, Inc., valued at $313,663 with the latest closing price.

DUNCAN RONALD A, the Director of GCI Liberty, Inc., sold 64,363 shares at the value of $61.03 during a trade that took place back on May 14, which means that DUNCAN RONALD A is holding 134,396 shares at the value of $3,927,954 based on the most recent closing price.

The current profitability levels are settled at -6.28 for the present operating margin and +38.34 for gross margin. The net margin for GCI Liberty, Inc. stands at +216.68. Total capital return value is set at -0.65, while invested capital returns managed to touch 23.64. Equity return holds the value 11.10%, with 5.70% for asset returns.

Based on GCI Liberty, Inc. (GLIBA), the companys capital structure generated 59.13 points for debt to equity in total, while total debt to capital is set at the value of 37.16. Total debt to assets is settled at the value of 29.91 with long-term debt to equity ratio rests at -0.36 and long-term debt to capital is 58.37.

EBITDA value lies at +73.59 M with total debt to EBITDA carrying the value of 16.88. The value for Enterprise to Sales is 11.84 with debt to enterprise value settled at 0.35. The receivables turnover for GCI Liberty, Inc. is 5.36 with the total asset turnover at the value of 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.

See the original post here:

GCI Liberty, Inc. (GLIBA) Gains 40.35% in one Year: Whats Next? - The News Heater

Year-End Gold and Bitcoin Price Predictions from Regular Everyday People | Featured – Bitcoin News

Posted on by

Just recently, news.Bitcoin.com talked to a number of individuals and asked them to let us know what they think the price of bitcoin and gold will be by the years end. Rather than leveraging the typical predictions from experts, executives, and crypto luminaries, the post delves into the perspective of average people and what they think about the future value of these assets.

Back in May 2016, I used a number of social media avenues in order to survey people on what they would do if bitcoin (BTC) touched the $10,000 mark. The article was very popular and of course, we all know that BTC reached the $10k zone the following year in 2017. Its been a long while since the 2017 bull run, so I decided to do the experiment once again leveraging my 4,700 friends on Facebook and a few members from a private crypto-focused Telegram channel.

Basically I asked what people think the price of bitcoin (BTC) and the price of one troy ounce of .999 fine gold will be by December 31, 2020. None of the participants are deemed experts, luminaries, or are billionaires with the same old predictions.

The people who answered are your average, everyday people who follow the cryptocurrency ecosystem. They also understand the faltering, manipulated monetary system bolstered by the central banking cabal as well. The first person who answered the price prediction question, an individual named Archer, said he believes bitcoin (BTC) will be $100,000. Archer also thinks the price of an ounce of gold will be $3,000 by the years end.

The Federal Reserve is pumping trillions of dollars into the economy, the U.S. is suffering civil unrest (and will likely suffer more, especially pre/post-election), Archer said explaining his rationale. Many city/state governments are near bankruptcy already, employment is at +30%, and will likely only get worse as the pandemic continues. I expect that there will be Greek-style bank shutdowns, capital controls, hyperinflation, negative interest rates, which will cause a flight to hard, portable assets.

A guy named Doug thinks bitcoin will be $16,000 by December 31, and gold will reach $3,300. Matt explained that he thinks gold will be $3,300 per ounce as well, but he expects BTC to jump to $35,000. Money printer go brrrrrrrr, is the rationale behind Matts reasoning. My old roommate Andy expects BTC to be valued at $21,243 and gold will be $4,116, but he also thinks a cow will be valued at $104,231.

Preston says BTC will be $24,000 by December 31 and gold will top $3,200 by the years end. I believe theyll be a significant price increase due to current unstable markets but due to reduction in monetary supply among lower classes, it wont completely go parabolic. Same with gold, Preston said explaining his forecasts reasoning.

Sarah gave me a random guess and said she thinks BTC will cross $33,000, while gold remains in the $2,000 range. Alfred said that he doesnt know much about gold but predicts BTC will be $10,100 by the years end. Alfred further explained his rationale:

People tend to spend more fiat during December, this will trigger more sell order plus miners recapitulation. The recent surge in price could be traced to the growing interest in an alternative source of income, which BTC seems to provide due to the closure of business activities plus growing interest in Defi in Ethereum blockchain. Things are returning to shape gradually and in the next quarter, I see the price stabilizing at $10,000 support level.

Andrew says with his prediction we will see BTC touch $15,000 per coin, while gold reaches $2,500. I think the main push for BTC will be from the retail side, Andrew stressed. The number of friends asking me how do I buy Bitcoin is at an all-time high reminds me of 2017. Gold will continue to rise for obvious reasons.

Steve says BTC will be $13,500 and gold will be $2,300 at the end of the year. Chris told me hes not a gold bug and thinks BTC will be anywhere between $8-12,000 by the years end. Another friend named Freya thinks gold will be $4,000 per ounce, but BTC will be $60,000.

BTC will be $23,500 and gold $2,400, said Rene. The issuance of more stimulus only serves to continue the devaluation of the dollar, and increase the value of more finite forms accepted as a store of value.

Adam seems to think BTC will be $15,500 and gold makes it to $5k by the end of the year. Hyperinflation causes Bitcoin to absorb debt and increase in value, where fiat does the opposite and devalues exponentially, Adam wrote. An individual named Colm said:

Bitcoin will be $33,000. Gold??? Its funny how folk buy gold but yet receive nothing. Silver maybe, but my trust is in blockchain.

The predictions were interesting and I got around 52 responses between Telegram and the Facebook channels leveraged. Interestingly, most of the gold predictions were relatively similar while BTC forecasts were all over the place. A number of others gave price predictions without reasoning as well. Daniel thinks BTC will be $17,000 and gold will be $2,390.

The participant Taylor gave me the lowest prediction for BTC with bitcoin at $5,400 and gold at $2,300. Tarik thinks the price of BTC will be $16,000 and the respondent Neeraj agrees.

BTC will be $16,000, Neeraj concluded. We will have heavy resistance at $20k and gold $2,500 as it moves slowly, but we are definitely knee-deep in inflation. With bitcoin, we could either be slowing down as we approach the all-time high (ATH) or touch it and come back to the handle part of the cup and handle that we always see before liftoff.

What do you think about the average peoples predictions about bitcoins and golds future price? Let us know in the comments section below.

Image Credits: Shutterstock, Pixabay, Wiki Commons

Disclaimer: This article is for informational purposes only. It is not a direct offer or solicitation of an offer to buy or sell, or a recommendation or endorsement of any products, services, or companies. Bitcoin.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

Link:

Year-End Gold and Bitcoin Price Predictions from Regular Everyday People | Featured - Bitcoin News

Raoul Pal: It May Not Be Worth Owning Any Asset Other Than Bitcoin – Cointelegraph

Posted on by

CEO and founder of Real Vision Raoul Pal says his conviction levels in Bitcoin are rising on a daily basis as he compares the crypto asset to traditional investments on various timescales.

Applying economic cycle theory in a series of charts posted to Twitter on Aug. 6, the former Goldman Sachs fund manager stated that although many investors choose gold as an alternative to fiat, Bitcoin (BTC) has been the only asset in the world to offset the growth of the G4 balance sheet. The G4 refers to the Bank of England, the Bank of Japan, the Federal Reserve, and the European Central Bank.

Its not stocks, not bonds, not commodities, not credit, not precious metals, not miners. Only one asset massively outperformed over almost any time horizon: Bitcoin.

G4 central bank balance sheet in Bitcoin terms. Source: RaoulGMI

The CEO continued:

My conviction levels in Bitcoin rise every day. Im already irresponsibly long. I am now thinking it may not be even worth owning any other asset as a long-term asset allocation, but that's a story for another day.

Pal told Cointelegraph in May that the devaluation of world currencies will cause the price of Bitcoin to rise 50x to 100x in the next five years. He interpreted economic cycle theory charts to mean the cryptocurrency could eventually reach $1 million.

As of this writing, the price of Bitcoin is approaching $11,800, having risen 6% in the last seven days.

Read more from the original source:

Raoul Pal: It May Not Be Worth Owning Any Asset Other Than Bitcoin - Cointelegraph

What Is the FIRE Movement? – Investment U

Posted on by

Financial Freedom

By Corey Mann

Originally posted August 3, 2020

Updated on August 6 at 4:59 pm

Are you looking for more information about the FIRE movement? If so, you have come to the right place. The FIRE retirement plan is growing in popularity across the United States.

Where did this movement begin? And does it actually work? Learn how saving your money and making smart investments can lead you on a path to early retirement.

First and foremost, FIRE stands for Financial Independence, Retire Early. Its a movement that is built around the ideas of frugality and investing.

It came about it 1992 through the bestselling book Your Money or Your Life by financial gurus Vicki Robin and Joe Dominguez. The FIRE movement has now been embraced by Millennials as a target to retire before the traditional age of 65.

This strategy has given individuals the ability to retire as early as their late 20s and early 30s. But you will need to save the majority of your yearly income to make it happen.

The model gained popularity back in the 2010s via online communities. Various blogs, podcasts and forums began discussing the FIRE movement while people began implementing its ideas into their own lives.

So, what is the FIRE retirement plan exactly? Its a goals-based approach to extreme saving and investing. And the ultimate goal is to reach 30 times your yearly expenses. For most people, that is roughly $1 million.

At this point, you can quit your day job or permanently retire. With the right investment plan, you can take out 3% to 4% each year sustainably. So the more you save up before retirement, the more you can take out later on.

However, the FIRE movement requires you to remain extremely vigilant with your finances. Youll need to remain frugal and monitor your expenses daily.

While you may be able to retire early, you will also have to reallocate your investments from time to time. This will ensure that you arent spending more than you can afford.

According to Social Security, the normal retirement age for anyone born after 1960 is 67. Its no wonder that so many people are trying to discover how to retire early. As each year passes and the cost of living rises, so does the projected retirement age.

The FIRE movement is built around extreme saving techniques, but that is just the foundation to the plan. And keeping your costs low is one of the most difficult parts. Therefore, its important to plan ahead in many aspects of your life.

Start by considering the rising costs of healthcare. If you retire at the age of 50, thats 15 years before youre eligible for Medicare. Some employers will offer healthcare benefits for retirees while others will have to receive their coverage privately.

This will need to go into your savings strategy as you begin to calculate how much money you need to live comfortably. Its also important to keep your other costs down as best as possible.

The FIRE movement doesnt work if you live above your means. You have to make a conscious decision to live below your means before retirement so that you can save enough to live comfortably after retirement.

This means you have to learn how to create a budget and stick to it. Cut costs as best as you can and eliminate your debts. Minimize the costs of your bills as best as possible, such as your cellphone. You dont need premium packages with added costs if youre living with FIRE.

The quickest route to an early retirement is the stock market. In fact, investing in stocks is the greatest form of passive income that can replace your paycheck. And the FIRE retirement plan suggests that you invest in low-cost index funds and dividend stocks.

For the latest stock market trends and analytics, sign up for the Investment U e-letter below. The experts at Investment U will help you find the quickest path to financial freedom with daily investing tips and trends.

Everyone wants to retire early, but are you frugal enough to make it happen? Learn more about the FIRE movement and discover how it fits your specific goals.

Here is the original post:

What Is the FIRE Movement? - Investment U

Wall Street keeps rallying; S&P 500 back within 2% of record – USA TODAY

Posted on by

Stan Choe and Alex Veiga, The Associated Press Published 10:56 a.m. ET Aug. 5, 2020 | Updated 7:04 p.m. ET Aug. 5, 2020

Where does the U.S. stimulus money come from? Here's how the Federal Reserve is saving the economy from the COVID-19 crisis. USA TODAY

Wall Streets big rally keeps rolling, and the S&P 500 rose for a fourth straight day Wednesday to sit just 1.7% below its record.

The S&P 500 climbed 21.26 points, or 0.6%, to 3,327.77, echoing gains for stocks across Europe and Asia. If the U.S. market has just a few more days like that, it will erase the last of the historic losses its taken since February because of the coronavirus pandemic and the recession it caused.

The Dow Jones Industrial Average rose 373.05, or 1.4%, to 27,201.52, and the Nasdaq composite added 57.23, or 0.5%, to set another record at 10,998.40.

Much of Wall Streets focus this week has been on Washington, where Congress and White House officialsare negotiatingon more aid for an economy thats shown some improvement but is still hobbling. Investors say such a package is crucial and needs to arrive quickly, with millions of Americans still out of work and $600 in weekly unemployment benefits from the U.S. government having recently expired.

COVID: Millennials, Gen Zers say pandemic has derailed their financial independence

'Insulin or groceries': How reduced unemployment affects struggling Americans from California to Mississippi

Treasury Secretary Steven Mnuchin said late Tuesday that the two sides set a goal of reaching an agreement by the end of the week to permit a vote next week, though negotiators said the two sides remain far apart on key issues.

The pressure on Washington to act quickly is mounting. A report on Wednesday suggested thathiring was far weakerlast month than economists expected. Private employers added just 167,000 jobs, according to a survey by payroll processor ADP, well below the 1.2 million that economists had forecast.

It highlights the damage that a resurgence incoronavirus casesacross much of the country is doing to the economy. It also puts an even brighter spotlight on Fridays more comprehensivejobs reportcoming from the Labor Department.

Investors across the stock market seem to be assuming that Congress will reach a deal sooner rather than later, as well as that the economy will continue to improve despite the pandemic, said Willie Delwiche, investment strategist at Baird.

If either one of those gets challenged, then you could see more volatility in stocks, he said.

(Photo: Getty Images)

The Walt Disney Co.rose 8.8% for one of the biggest gains in the S&P 500 after the media giant reported a profit for the spring that beat Wall Streets expectations, even if it was down sharply from a year earlier.

Prudential Financial rose 6.2%, helping to drive the financial sector to one of the markets bigger gains, after it likewise reported results that werent as bad as analysts had forecast.

Thats been the trend across much of the market this reporting season. Stocks have continued to climb even though S&P 500 companies appear to be on track to report a roughly 34% drop in earnings per share from a year earlier, according to FactSet. Thats in part because investors had prepared for an even steeper drop.

The overall theme from earnings has been not as bad as we feared, Delwiche said. Estimates came down, and now everybodys beating that really low bar. Management is as in the dark as everyone else, in terms of what the path of this recovery is going to be. Everyone is kind of waiting to see what happens next in terms of the recovery.

Investors are betting that the plunge in profits will prove to be only temporary and that earnings will recover as economies reopen and a vaccine for the new coronavirus hopefully gets developed to help the world get closer to normal.

Shares of biotech company Novavax jumped 10.4% after it reported data on its vaccine candidate for COVID-19. Analysts cautioned not to over-interpret the data but called it encouraging.

A better-than-expectedreadingon the nations services sector also added to the mixed picture on the economy. The services sector includes retail, health care and transportation, and it makes up the bulk of the U.S. economy. It grew in July for the second straight month, according to a survey by the Institute for Supply Management, and accelerated when economists were expecting a slight slowdown.

Even within that report, though, were seeds of concern. Growth in new orders helped to drive the reading higher, but employment trends in the report werent as encouraging.

Treasury yields rose, reclaiming some of their lost ground from a day before when they sank to a nearly five-month low. The yield on the 10-year Treasury climbed to 0.54% from 0.51% late Tuesday.

Yields have remained very low as investors have continued to worry about the weak economy and as the Federal Reserve has unleashed massive amounts of stimulus.

Gold rose even further into record territory, continuing its strong climb since the spring amid nervousness about the economy and super-low interest rates. Gold for delivery in December, the most actively traded contract, rose $28.30 to settle at $2,049.30 per ounce.

In Europe, Germanys DAX returned 0.5%, and Frances CAC 40 rose 0.9%. The FTSE 100 in London added 1.1%.

In Asia, Japans Nikkei 225 slipped 0.3%, but South Koreas Kospi added 1.4%. Hong Kongs Hang Seng rose 0.6%, and stocks in Shanghai inched up 0.2%.

Benchmark U.S. crude rose 49 cents to settle at $42.19 per barrel. Brent crude, the international standard, added 74 cents to $45.17 a barrel.

Read or Share this story: https://www.usatoday.com/story/money/2020/08/05/wall-street-rallies-again-track-fourth-straight-gain/3298709001/

Originally posted here:

Wall Street keeps rallying; S&P 500 back within 2% of record - USA TODAY

Water, sewer rates proposed to increase | News – The Central Virginian

Posted on by

The Louisa County Water Authority will hold a public hearing on Aug. 12 on proposed changes to water and sewer rates paid by their 850 customers, including the town of Louisa.

Rates are slated for an increase to cover growing operational costs, and the authority proposes a new $6 monthly administrative fee.

But the authority is also lowering the base rate from 4,000 to 3,000 gallons per month. The latter change will credit customers who have historically used less water each month than the base amount.

A lot of people, especially those on fixed incomes, use way less than 4,000 gallons, said Pam Baughman, water authority general manager. This ends up saving one-third of our customers some money.

She said a rate increase is needed to keep up with state and federal regulations, and to help the authority work toward financial independence from the county government.

Were closing the gap and have made improvements to be more efficient, but those cost money, she said.

The rate changes affect customers who get their water from Northeast Creek Reservoir and the county wells in the Green Springs area. The water authority treats wastewater at the regional plant just outside the town of Louisa and at its Zion Crossroads facility.

The current base water and sewer rates are $23.56 and $35.48 per 4,000 gallons. The new base rates would be $20.13 and $29.79 per 3,000 gallons.

The water rate per 1,000 gallons would increase from $5.89 to $6.71, and the sewer rate per 1,000 gallons from $8.87 to $9.93.

Even after paying the new administrative fee, a customer using only 3,000 gallons per month would see a savings over current rates. But a customer who continues to use close to 4,000 gallons per month will pay significantly more.

The wholesale user rate per 1,000 gallons, which the town of Louisa pays, is proposed to climb from $4.57 to $5.21. The Louisa Town Council indicated last month it will wait to see what action the water authority takes before deciding whether to change rates for town customers.

The public hearing on the rate changes will begin at 6 p.m. on Aug. 12 in the public meeting room at the Louisa County Office Building, 1 Woolfolk Avenue. In-person access will be limited to the first 28 citizens who want to speak. The meeting will be streamed live on the county website and people can also call 540-967-0401 during the meeting to make comments.

Go here to read the rest:

Water, sewer rates proposed to increase | News - The Central Virginian

Beyond Motherhood: Powerful Women in Politics – Armenian Weekly

Posted on by

This week in our empowerment series we meet three phenomenal women U.S. Representative Anna G. Eshoo (D-CA-18), U.S. Representative Jackie Speier (D-CA-14), and Speaker of the Maine House of Representatives Sara Gideon.

Together they exemplify what it means to be a strong leader blazing trails, empowering women, all while supporting the Armenian American community.

Rep. Anna Eshoo

First, we meet Representative Anna Eshoo. Born in New Britain, Connecticut, Rep. Eshoo is both Assyrian and Armenian and has represented Californias 18th congressional district since 1993.

The first woman elected to serve as Chair of the Health Subcommittee, Rep. Eshoo also serves as the Ranking Member on the Subcommittee on Communications and Technology, as well as the House Energy and Commerce Committee. During her time in office, she has fought for consumers, access to health care for families, advocated for the development of clean energy technology and protected the environment. In order to provide citizens with affordable health insurance, she has drafted parts of the Affordable Care Act and continues to strengthen this law.

Rep. Eshoo has left an indelible mark on US policy from her work on the landmark Telecommunications Act of 1996 to her work in helping fund Next Generation 911 technology following the tragic events of September 11. Recognized as one of the 10 most powerful women in Silicon Valley, she has also been awarded the Statesmanship Award for her commitment to improving the lives of others.

As the only Armenian-Assyrian in Congress, Rep. Eshoo who has served as a co-sponsor of the Armenian Genocide Resolution since 1993, took pride in leading the bipartisan effort to move the Armenian Genocide Resolution, H.Res.296, to the House floor for a vote in 2019. The bipartisan resolution which passed with an overwhelming vote of 405 to 11 fights denial of the Armenian Genocide and encourages truth and justice.

In response to the passage of the resolution, Rep. Eshoo stated, Between 1915 and 1923, 1.5 million Armenians, and hundreds of thousands of Assyrians, Greeks, Syriacs, Arameans, Maronites, and other Christians were systematically slaughtered at the hands of the Ottoman Empire There is an historic parallel today as Turkey is once again engaging in ethnic cleansing, this time against the Kurds in Syria. This resolution not only honors and commemorates my ancestors and all those who perished in the first genocide of the 20th century but serves as a timely reminder that we must remain vigilant to prevent similar atrocities today.

A proud mother of two children, Rep. Eshoo received her degree from Canada College and the CORO Foundation. In 1982, she was voted to the San Mateo County Board of Supervisors where she went on to serve the County Board for 10 years before she became a member of the U.S. House of Representatives.

Rep. Jackie Speier

Another powerhouse in the halls of Congress is Rep. Jackie Speier an Armenian American politician who has served as a US Representative for Californias 14th congressional district since 2008.

A staunch supporter for womens equality, LGBTQ rights and cleaning up government corruption, she was named in Newsweeks top 150 Fearless Women in the world, as well as one of the most influential people in American politics in Politicos 50.

She serves on the Subcommittees on Environment and Government Operations and is also Co-Chair of the Democratic Womens Caucus, Congressional Armenian Caucus, Bipartisan Task Force to End Sexual Violence, and the Gun Violence Prevention Task Force.

A staunch advocate against sexual assault in the military as well as on college campuses, she had over 300 bi-partisan bills signed into law that have helped achieve justice for women and children. Rep. Speier introduced the Me Too movement in the halls of Congress in October 2017, later becoming the basis of the bipartisan Congressional Accountability Act and Reform Act that was signed into law in December 2018.

Although shes had several wins, shes also faced her fair share of challenges. For instance, when Rep. Speier started working on implementing sexual harassment training in Congress in 2014, she was told that anti-harassment training would never take place. However, the CAA Reform Act made sure that anti-harassment training was mandatory.

She tells the story of one of her most tragic and challenging encounters in her book, Undaunted: Surviving Jonestown, Summoning Courage, and Fighting Back. In it, she shares her traumatic experience in Jonestown, Guyana, where she joined the late Congressman Leo Ryans delegation in rescuing defectors from Jim Joness Peoples Temple. Congressman Ryan was murdered, and Rep. Speier was shot five times.

Recovering from this traumatizing experience, she decided that she wanted to show her strength rather than her weakness and fight against inequality and injustice in the U.S. Congress. Her experience highlights her strong leadership and character as she fought her hardest to stay alive and use her voice to help others.

She brings that same passion to the Armenian cause. As co-chair of the Congressional Caucus on Armenian Issues and one of three Armenian American members of Congress, she was a relentless advocate for passage of H.Res.296, the Armenian Genocide resolution.

On the heels of the passage of the resolution, she said, The Houses resounding 405-11 vote to recognize the Armenian Genocide is a great victory for millions of Armenians around the world. Congress has failed to affirm the truth for far too long and Im heartened that we have joined our allies around the globe, and 49 U.S. states, in acknowledging that the Ottoman Empire perpetrated a genocide upon the Armenian people. She went on to say, This vote also sent a critically important message to the world in light of Turkeys modern-day ethnic cleansing campaign of the Kurds in Syria. Today, we sent a message that history cant be rewritten, that America will no longer abandon Armenians with feeble excuses for a so-called ally, and that we will never forget the atrocities of the past and present. Today we affirmed the Armenian Genocide was real and we stand against it and those who seek to perpetuate such evil again.Speier received her B.A. in Political Science from the University of California at Davis and her J.D. from UC Hastings College of the Law. A proud wife and mother, Gideon focuses on making the lives of working families easier, particularly in the current economy.

Maine House Speaker Sara Gideon

Lastly, we meet Sara Gideon, speaker of the Maine House of Representatives. Speaker Gideon, who is of Indian and Armenian descent, is running for US Senate in Maine with a focus on public interest. Speaker Gideon recently won the Democratic primary for the US Senate seat in Maine challenging the seat held by Senator Susan Collins.

During her time in the Maine House of Representatives, she passed a landmark bill in order to provide tax refunds to homeowners in Maine and has focused on opening up more educational opportunities for the people of Maine to have a chance at financial independence.

Additionally, she has addressed delivering resources to battle Maines opioid epidemic. Former Governor Paul Lepage went against Saras opioid legislation, however, that did not result in her giving up. Instead, she brought both political parties together to overturn the veto.

Shes exhibited passion and dedication in her work for the people of Maine, and she brings that same conviction to the campaign trail.

Shes had opportunities to connect with Armenian Americans throughout the region. This past April 24, 2020, she stood by the Armenian American community of Maine in commemorating the 105th anniversary of the Armenian Genocide. As the granddaughter of Armenian refugees, I hold this day as a solemn reminder that we must continue our work to protect human rights, Gideon said.

Outside of her advocacy work, she also helped secure recognition of Artsakhs independence for the state of Maine.

A wife, mother and graduate from George Washington University in International Affairs, Speaker Gideon is poised for a seat in the US Senate.

Whether they are in the halls of Congress, on a trip to Armenia or a stop on the campaign trail, these women have made incredible strides in advancing issues that are paramount to the marginalized. They have used their platforms to advance matters that are not only central to their beliefs and the broader communities they serve, but they have also continuously advocated for the Armenian American communities they represent and the Armenian cause.

We look forward to a day in which the next generation of leaders ascends into the ranks that these women have achieved. They are truly making a difference on the inside in the halls of Congress even and that helps us advance the cause.

Tvene Baronian is a rising sophomore attending Hobart and William Smith Colleges in Geneva, New York. She plans to graduate with a double major in Environmental Studies and English. On campus, Tvene is a member of the Environmental Club, Campus Green Club, Public Leadership Education Network (PLEN), Outdoor Recreation Adventure Program (ORAP), Sustainability Club, Koshare Dance Collective, and the Lacrosse Club. In addition to her involvement on campus, her passion for her Armenian heritage drives her participation in various volunteer organizations including Armenian Youth Federation (AYF), Hamazkayin Nayiri Dance Ensemble, HMEM Scouts and the Armenian National Committee of America (ANCA). During her free time, she loves to sing, dance, write and draw. She has a passion for music and has performed at Carnegie Hall, where she showcased her love of Armenian opera.

Go here to read the rest:

Beyond Motherhood: Powerful Women in Politics - Armenian Weekly

All you need is WiFi: How Covid-19 could bring in the era of the digital nomad – Hindustan Times

Posted on by

Digital nomads are defined as professionals who live in a nomadic manner and work remotely, usually operating out of coffee shops, co-working spaces and even, while staycationing in another country. All you need in a lifestyle like this, is a constant internet connection and a laptop or smartphone. Most people choose to become digital nomads for positive reasons, including financial independence and a career that allows one to work from anywhere. The downside, however, is that these set of professionals might feel lonely or easily burnt out when theyre constantly connected to the digital ecosystem - a pattern several professionals have been battling with in the last 5 months weve been adapting to work from home.

The term Digital Nomad was first-heard in the book by the same name, written by Tsugio Makimoto and David Manners in 1997, however, theres no evidence to prove that the term was coined here first or pre-existed. Digital nomads are known to adapt to a minimal lifestyle and may also sell a number of possessions in order to travel lighter and be able to move around easily, without baggages, figuratively and literally.

In the pandemic and post-pandemic world, when travel is looking different as per the forecasts and is expected to serve different purposes for everyone, the term digital nomadism has been doing the rounds again. Countries, especially those whose economies are heavily-dependent on tourism, are competing for a new generation of remote workers in a bid to ride out the pandemic and make up for lost visitors, by offering sunny beaches, cheap living and low infection rates.

A blog called digitalnomads.com reported in 2017 that Bangkok was a digital nomad hub as it only costs $280 per week to live here.

From Barbados to Estonia, several countries are launching visa regimes aimed at wooing digital nomads to revive their tourism-dependent economies, chasing the sort of people who mix work with travel and can set up shop any place with an internet connection.

Work from Paradise, as Barbados 12-month Welcome Stamp Visa boasts, launched in July allowing remote workers to relocate to the Caribbean island for one year.

Our new... (visa) allows you to ... work from one of the worlds most beloved tourism destinations, the countrys Prime Minster Mia Mottley wrote in a welcome message on the page.

Even before the pandemic, numbers were growing, with more than 7 million people in the United States calling themselves digital nomads in 2019, up from about 5 million in 2018, according to research from the firm.

Countries launching the new visa regimes hope that luring some of them could help stimulate local economies hit by the new coronavirus and make up for some of the lost tourism.

Digital Nomad Visa

Estonia launched a Digital Nomad Visa last week in an endeavour to boost the countrys credentials as an innovation hub. The main aim of the programme is to promote Estonia, Annus told the Thomson Reuters Foundation, explaining the scheme was one of the first in the world to target remote-working employees, as well as freelancers and contractors. The more known Estonia is, the more our companies can export our e-services and more and more people are interested in investing ... and of course ... the more tourists we shall have.

In Georgia, which also announced plans for a digital nomad visa last month, economy minister Natia Turnava said she hoped to shore up the countrys real estate and hospitality sectors.

Georgia has an image of a safe country in terms of epidemiological standpoint and we want to use this chance, the local media reported her saying.

Barbados and the North Atlantic British territory of Bermuda - which launched a Work from Bermuda one-year residential certificate this week - also flaunted their virus credentials.

No need to be trapped in your apartment in a densely populated city with the accompanying restrictions and high risk of infection, Bermudas premier David Burt wrote online.

Come spend the year with us working or coding on the water, they added.

In Bermudas Work from Bermuda Certificate Program, visitors only have to show valid healthcare insurance, and pay an online fee of $263. This will allow them to come and work in the country, and leave as often as they like for a year-long period.

Estonia is asking that applicants prove they earn at least 3,504 euro ($4,100) a month, while those moving to the Barbados have to pay a $2,000 fee.

Follow more stories on Facebook and Twitter

See more here:

All you need is WiFi: How Covid-19 could bring in the era of the digital nomad - Hindustan Times